Cellular differentiation

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

Retrieved on:

Friday, July 16, 2021

Life sciences, Biology, Biotechnology, Induced stem cells, Developmental biology, Stem cells, IPSCS, Biopharmaceutical, Cellular differentiation, Induced pluripotent stem cell

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Key Points:

The archived webcast will be available on the Company's website beginning approximately two hours after the event.
Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Global Induced Pluripotent Stem Cells Markets 2021-2026: Molecular and Cellular Engineering, Cellular Reprogramming, Cell Culture, Cell Differentiation, and Cell Analysis - ResearchAndMarkets.com

Retrieved on:

Thursday, June 24, 2021

Health, Stem cells, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Stem cell genomics

The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.
Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
For this report, iPSC products do not cover stem cell research and clinical products, which are broadly applicable to any stem cell type.
An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSCs market.

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Retrieved on:

Thursday, June 24, 2021

Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Cell therapy

Upon completion, the acquisition will build upon Catalent's existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.

Key Points:

Upon completion, the acquisition will build upon Catalent's existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.
iPSCs are cells that can be differentiated into various cell types to address a wide range of therapeutic indications.
"We formed RheinCell based on our deep scientific and regulatory expertise in the promising field of cell-based therapies," commented Juergen Weisser, Chief Executive Officer, RheinCell Therapeutics.
RheinCell develops and manufactures GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies.

Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors

Retrieved on:

Wednesday, May 5, 2021

Infectious diseases, Stem cells, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Optical, Oncology, Branches of biology, Biology, Developmental biology, Induced stem cells, Life sciences, Cellular differentiation, Stem cells, Biotechnology

Dr. Jayasuriya is a successful healthcare private equity executive and venture capitalist with extensive clinical, industry, entrepreneurial, and investment experience.

Key Points:

Dr. Jayasuriya is a successful healthcare private equity executive and venture capitalist with extensive clinical, industry, entrepreneurial, and investment experience.
and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School.\n\xe2\x80\x9cDr.
We are delighted she will be joining our Board of Directors,\xe2\x80\x9d stated Al Kingsley, Lineage\xe2\x80\x99s Chairman of the Board.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021

Retrieved on:

Tuesday, May 4, 2021

Infectious diseases, Biotechnology, Health, Oncology, Branches of biology, Biology, Stem cells, Life sciences, Lineage Cell Therapeutics, Induced stem cells, Developmental biology, Cellular differentiation

b'Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 13, 2021, following the close of the U.S. financial markets.

Key Points:

b'Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 13, 2021, following the close of the U.S. financial markets.
A live webcast of the conference call will be available online in the Investors section of Lineage\xe2\x80\x99s website.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.
For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005098/en/\n'

Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting

Retrieved on:

Tuesday, April 27, 2021

Branches of biology, Biology, Medical specialties, Immune system, CD16, Natural killer cell, Antibody-dependent cellular cytotoxicity, Antibody, Cellular differentiation, Induced pluripotent stem cell, Induced stem cells

Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.

Key Points:

Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
The Company\xe2\x80\x99s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.
CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells.
Fate Therapeutics is headquartered in San Diego, CA.

Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021

Retrieved on:

Monday, April 26, 2021

Additional videos are available on the Media page of the Lineage website.\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Key Points:

Additional videos are available on the Media page of the Lineage website.\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
Lineage\xe2\x80\x99s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.
For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005027/en/\n'

Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors

Retrieved on:

Thursday, April 22, 2021

Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, IQVIA, Developmental biology, Induced stem cells, Cellular differentiation

Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development.

Key Points:

Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development.
Amin spent more than 20 years at Quintiles Transnational (now IQVIA), the world\xe2\x80\x99s largest provider of biopharmaceutical development & commercial outsourcing services.
Dr. Amin is an Honorary Lecturer in Clinical Pharmacology at Guy\xe2\x80\x99s, King\xe2\x80\x99s, and St. Thomas\xe2\x80\x99 Hospitals Medical & Dental Schools.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Retrieved on:

Tuesday, April 20, 2021

b'Immunomic Therapeutics, Inc., (\xe2\x80\x9cITI\xe2\x80\x9d), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today a worldwide license and development collaboration agreement with Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions.

Key Points:

b'Immunomic Therapeutics, Inc., (\xe2\x80\x9cITI\xe2\x80\x9d), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today a worldwide license and development collaboration agreement with Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions.
Lineage and ITI will collaborate in the manufacturing and clinical development of a novel VAC product candidate.
\xe2\x80\x9cOver the last several years, ITI has invested significant capital and development resources to identifying multiple novel paths forward in GBM.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

Retrieved on:

Tuesday, April 20, 2021

The collaboration will generate a novel product candidate derived from Lineage\xe2\x80\x99s VAC allogeneic cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by ITI, for the treatment of glioblastoma multiforme (GBM).

Key Points:

The collaboration will generate a novel product candidate derived from Lineage\xe2\x80\x99s VAC allogeneic cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by ITI, for the treatment of glioblastoma multiforme (GBM).
Lineage and ITI will collaborate in the manufacturing and clinical development of a novel VAC product candidate.
\xe2\x80\x9cThis collaboration represents the first of many partnerships we hope to enter into with our platform and we believe it helps further validate VAC as a promising new therapeutic vaccine platform.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.